Immuno-Oncology

Heather A. Wakelee, MD, associate professor of Medicine (Oncology), Stanford University Medical Center, discusses how immunotherapy agents compare with targeted therapies in patients with non–small cell lung cancer who harbor genetic alternations.

Mark W. Kris, MD, discusses immunotherapy, frontline therapies for nonsquamous non–small cell lung cancer, and advancements in squamous cell carcinoma.

Shirish Gadgeel, MD, discusses the KEYNOTE-021 and KEYNOTE-189 studies, which are both examining pembrolizumab with chemotherapy in patients with non–small cell lung cancer.

Avelumab, a fully human anti–PD-L1 IgG1 antibody, showed activity in patients with heavily pretreated recurrent or refractory ovarian cancer with an acceptable toxicity profile.

Raffaele Califano, MD, discusses the KEYNOTE-028 and CheckMate-032 trials, the role of PD-L1 as a biomarker in small cell lung cancer, and what is on the horizon for immunotherapies in the landscape of SCLC.

Akash Patnaik, MD, discusses immunotherapy and personalized medicine tactics in the field of prostate cancer, as well as the work that needs to be done with existing targeted therapies and biomarker development.

The FDA has granted a priority review designation to nivolumab as a treatment for patients with previously treated metastatic or recurrent squamous cell carcinoma of the head and neck.